Business Type: Manufacturer, Distributor/Wholesaler
Employees Total 11-50
Annual Revenue US$10 Million - US$50 Million
OVERVIEW
There are currently no SARS-CoV-2-specific treatments or vaccines available due to the novelty of the virus. Hence, rapid Development of effective vaccines against SARS-CoV-2 are urgently needed. Hence, our Developer initiated R&D of COVID-19 vaccine on Jan. 28, 2020, and se 1 and 2 Trials were approved by NMPA on April 13, 2020. As of today, se 3 trials have been approved in Brazil, Indonesia, Turkey and Bangladesh. More than 30,000 subjects have been enrolled in these se 3 trials. Neutralizing antibodies successfully produced by the subjects’ body after 2 doses, providing partial or complete protection In macaques against Covid-19 challenge, with no adverse side effects observed in the subjects.
INTERNATIONAL COORDINATION OF DEVELOPER
        DCVMN- Developing Countries Vaccine Manufacturers Network
        IFPMA- International Federation of rmaceutical Manufacturers & Associations
        WHO- World Health Organization
        PAHO- Pan America Health Organization    Â
        UNICEF- FOR EVERY CHILD
QUALITY ACCREDITATION OF DEVELOPER
        Total GMPs: 11 Certificates
        Toral MAs: 33 product Certificates
TECHNOLOGY- based on inactivated whole vision technology.
